Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS (VRTX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CET

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
12/14 VERTEX PHARMACEUTICALS : CF Children, Ages 1-2, Safely Treated with Kalydeco
12/14 VERTEX PHARMACEUTICALS : and CRISPR Therapeutics to Co-Develop and Co-Commercial..
12/13 VERTEX PHARMACEUTICALS : makes first pick in CRISPR collaboration
12/11 NASDAQ 100 MOVERS : Orly, bmrn
12/11 VERTEX PHARMACEUTICALS : Announces Positive Results from Open-Label Phase 3 Stud..
12/09 Tax-loss selling to pressure 2017's losers in December
12/07 VERTEX PHARMACEUTICALS : Announces Positive Results from Open-Label Phase 3 Stud..
11/21 VERTEX PHARMACEUTICALS : Receives CHMP Positive Opinion for ORKAMBI® lumacaftor/..
11/20 S&P 500 MOVERS : Vrtx, dlph
11/16 VERTEX PHARMACEUTICALS : Announces Presentations of Data at North American Cysti..
More news
News from SeekingAlpha
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Premarket analyst action - healthcare
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 CRISPR Therapeutics and Vertex team up to advance and commercialize lead gene..
12/12 CUTTING EDGE GENE THERAPIES : Beta-Thalassemia Breakthroughs (Part I)
Financials ($)
Sales 2017 2 347 M
EBIT 2017 537 M
Net income 2017 278 M
Finance 2017 902 M
Yield 2017 -
P/E ratio 2017 154,92
P/E ratio 2018 82,04
EV / Sales 2017 15,3x
EV / Sales 2018 13,0x
Capitalization 36 888 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 183 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith Chief Operating Officer & Executive Vice President
Thomas Graney Chief Financial Officer & Senior Vice President
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS96.55%36 888
GILEAD SCIENCES6.94%98 689
REGENERON PHARMACEUTICALS5.33%41 789
GENMAB-11.85%9 967
BLUEBIRD BIO INC199.68%8 385
EXELIXIS, INC.78.27%7 722